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Abstract 
Currently, the number of patients with COVID-19 has significantly increased. Thus, there is an 
urgent need for developing treatments for COVID-19. Drug repurposing, which is the process of 
reusing already-approved drugs for new medical conditions, can be a good way to solve this 
problem quickly and broadly. Many clinical trials for COVID-19 patients using treatments for other 
diseases have already been in place or will be performed at clinical sites in the near future. 
Additionally, patients with comorbidities such as diabetes mellitus, obesity, liver cirrhosis, kidney 
diseases, hypertension, and asthma are at higher risk for severe illness from COVID-19. Thus, 
the relationship of comorbidity disease with COVID-19 may help to find repurposable drugs. To 
reduce trial and error in finding treatments for COVID-19, we propose building a network-based 
drug repurposing framework to prioritize repurposable drugs. First, we utilized knowledge of 
COVID-19 to construct a disease-gene-drug network (DGDr-Net) representing a COVID-19-
centric interactome with components for diseases, genes, and drugs. DGDr-Net consisted of 592 
diseases, 26,681 human genes and 2,173 drugs, and medical information for 18 common 
comorbidities. The DGDr-Net recommended candidate repurposable drugs for COVID-19 through 
network reinforcement driven scoring algorithms. The scoring algorithms determined the priority 
of recommendations by utilizing graph-based semi-supervised learning. From the predicted 
scores, we recommended 30 drugs, including dexamethasone, resveratrol, methotrexate, 
indomethacin, quercetin, etc., as repurposable drugs for COVID-19, and the results were verified 
with drugs that have been under clinical trials. The list of drugs via a data-driven computational 
approach could help reduce trial-and-error in finding treatment for COVID-19.  
 
 
 
  
1. Introduction 
Coronavirus typically affects the respiratory tract of humans, and it leads to mild severe respiratory 
tract infections. Since December 2019, the novel coronavirus, well known as severe acute 
respiratory syndrome coronavirus 2 (SARS-COV-2) or coronavirus disease 2019 (COVID-19), 
has been declared a global pandemic by the World Health Organization1. As of June 14th, there 
are about 755 million confirmed cases and about 42.3 million deaths worldwide. The most 
common symptoms of COVID-19 are fever, dry cough, and fatigue. Additional symptoms include 
nasal congestion, headaches, conjunctivitis, and sore throat. In severe cases, symptoms of 
dyspnea and chest pain were reported.  
Several recent studies analyzed hospitalized patients’ records to investigate diseases comorbid 
with COVID-19. Patients with these comorbidities such as diabetes mellitus, obesity, liver cirrhosis, 
kidney diseases, hypertension, and asthma have a higher risk for severe illness from COVID-192-
7. Among confirmed cases of COVID-19, patients with any of the above comorbidities do worse 
than those without. Since the coronavirus leads to death in severe cases and is highly contagious 
between humans, there is an urgent need for developing therapeutic treatments or vaccines. 
However, there are currently no effective medications8.  
To overcome the pandemic, many researchers and companies are currently developing new 
treatments and vaccines for COVID-19. However, this process usually takes at least a decade of 
work and about $300-600 million of funding. In order to overcome this global pandemic quickly, 
treatments must be developed immediately, but this can be difficult if we only employ traditional 
drug discovery methods. One way to hasten our search for effective treatments involves drug 
repurposing. Drug repurposing (or drug repositioning) is the process of reusing of already-
approved drugs for new medical conditions. Many clinical trials for COVID-19 patients using 
treatments for other diseases are already in place or will be performed in the clinical sites shortly10. 
So far, candidate treatments such as Remdesivir (originally designed to treat the Ebola virus), 
hydroxychloroquine (the now-infamous malaria drug), and lopinavir/ritonavir (an antiretroviral 
drug targeting HIV) have been used on hospitalized COVID-19 patients. In addition to these 
clinical trials, many studies have recently been conducted using computational drug repurposing 
strategies. Zhou et al constructed a drug-human coronavirus network using protein associations 
between coronavirus and 2,938 drugs and discovered 16 repurposable drugs11. They constructed 
a protein interactome network using coronavirus and drug-related genes and then predicted 
candidate drugs using network proximities. Ge et al proposed a data-driven drug repurposing 
framework that integrates coronavirus-related data and identifies drug candidates from 6,255 
drugs12. Muralidharan et al found candidate drugs capable of molecular docking or drug binding 
by modeling the protein structure of coronavirus and drugs with structure-based virtual screening 
identified four commercially available drugs13. These previous studies used only protein/gene 
information or the molecular structure of coronavirus that can be targeted by repurposable drugs. 
This means that unfortunately clinical information has not been utilized. Because COVID-19 
patients with comorbidity disease have a high risk of illness, this unexplored relationship of 
comorbidity disease may help to find repurposable drugs. 
In this study, we propose a network-based drug repurposing framework to predict candidate 
therapeutic agents for COVID-19. Our framework combines heterogeneous relational data such 
as disease-gene associations, disease-drug associations, drug-target gene associations, and 
comorbidity information with the novel coronavirus. Initially, we construct the comprehensive 
disease-gene-drug association networks by combining the disease-disease networks, gene-gene 
networks, and drug-drug networks. Then, the network propagation algorithm is applied to predict 
candidate repurposable drugs for COVID-19.   
In more detail, from the associations between diseases, genes, and drugs, we construct a 
disease-gene-drug network (DGDr-Net) to understand the interactions between diseases, genes, 
and drugs. Then, the comorbidity information was added to the DGDr-Net to enhance the 
interactions between COVID-19 and other diseases. The constructed networks have tripartite 
relationships among diseases, genes, and drugs and these interactions can be represented in 
the form of layered networks. In establishing a tripartite relationship between a specific disease, 
gene, and drug, the following three procedures should be considered for drug repurposing: (1) 
Find a disease that is genetically or clinically similar to COVID-19 (at the disease level); (2) Find 
the key gene that serves as the bio-marker or some other therapeutic evidence for COVID-19 at 
the gene level; (3) Find a drug that can be used to treat COVID-19 by combining or finding a drug 
that is already being used to treat other diseases. Given the nature of tripartite relationships, all 
three steps need to be done simultaneously rather than independently. Thus, we construct a 
disease-gene-drug network consisted of three single-layered networks: a disease-disease 
network (disease layer), a gene-gene network (gene layer), and a drug-drug network (drug layer). 
Additionally, each single network is connected according to association information. Within the 
network, drug scores for COVID-19 are calculated by network-based label propagations that are 
using graph-based semi-supervised learning. Since the treatments of COVID-19 are not yet found, 
there is no label information associated with COVID-19 in the drug network. In those cases, the 
semi-supervised approach that can be applied when label information is insufficient is a very 
suitable method for recommending candidate drugs14, 15. Semi-supervised learning can deal with 
few labeled data and can perform predictions by propagating the label information to unlabeled 
nodes along with edges16. When the COVID-19 in the disease layer is set as a seed node for 
propagation, then the label information is transmitted through the edges of the disease-gene-drug 
network. The comorbidity and disease-gene association information in the disease layer are 
propagated to the gene and drug layer to inform the priority of the repurposable drug of COVID-
19. From the resulting scores, the priorities of candidate drugs can be identified. The top-tier 
candidate drugs are recommended by repurposable drugs for coronavirus. The predicted results 
can help reduce trial-and-error in finding treatment for COVID-19. 
2. Methods 
We propose a network-based drug repositioning method that utilizes and integrates biochemical 
and clinical COVID-19 data such as disease comorbidity, protein associations, and drug-target 
gene information. The overall framework to find repurposable drugs for treating COVID-19 
consists of mainly two parts as shown in Figure 1: (a) Constructing a Disease-Gene-Drug network 
and (b) Scoring for candidate repurposable drugs. We first construct the Disease-Gene-Drug 
networks (DGDr-Net) to figure out the interactions between the biological components related to 
COVID-19. The constructed networks have tripartite relationships among diseases, genes, and 
drugs and these interactions can be represented in the form of layered networks. Next, drug 
scores for COVID-19 are calculated by network-based label propagations using graph-based 
semi-supervised learning14, 15, 17. From the resulting scores, the priorities of candidate drugs can 
be identified. The top-tier candidate drugs are recommended by repurposable drugs for 
coronavirus. 
 
Figure 1. Schematic description for the proposed method: a) Disease-Gene-Drug networks 
with COVID-19, b) scoring results with genes/drugs for targeting COVID-19,  
a) b)
2.1 Disease-Gene-Drug network 
We construct the Disease-Gene-Drug Networks (DGDr-Net) to show the COVID-19 centric 
interactome with components for diseases, genes, and drugs. The interactions among them have 
a tripartite relationship that can be represented in the form of layered networks. The DGDr-Net is 
a graph,	𝐺 = (𝑉, 𝐸, 𝑆), where 𝑉 represents the set of nodes, 𝐸 represents the set of edges, and 𝑆 
represents the set of layers. The proposed networks have three single layers with 𝑆 = {𝑆! , 𝑆" , 𝑆!#}, 
depending on the type of components (e.g., disease, gene, and drug) as shown in Figure 1(a). In 
the network, let 𝑣$ ∈ 𝑉 denote a node and 𝑒$% ∈ 𝐸 to denote the edge that connects two vertices 𝑣$ and 𝑣%. The edge weights in the single layer have weighted values and unweighted values 
between different layers. The edge weights in a single layer 𝑤$% between two nodes 𝑣$ and 𝑣% is 
calculated by Gaussian similarity kernel as follows: 
				𝑤$% = 0exp(− &'()*+!,+"-.# )	 , 𝑣$ ∼ 𝑣%0																, 𝑣$ ≁ 𝑣% 		                                    (1) 
where dist(𝑣$ , 𝑣%) is a distance measure for adjacent nodes (𝑣$ ∼ 𝑣%). The edge values between 
different layers can take a value 1 if the associations exist, otherwise 0. Then, the value of the 
similarity for DGDr-Net is represented by a matrix 𝑾 = {𝑤$%}. To easily describe the DGDr-Net 
with three single layers, the similarity matrix 𝑾 can be expressed in block-wise as follows: 
𝑾 = = 𝑊/ 𝑊/~1 𝑊/~/2𝑊/~13 𝑊1 𝑊1~/2𝑊/~/23 𝑊1~/23 𝑊/2 ?                                                    (2) 
The block diagonal matrix (𝑊/,𝑊1, and	𝑊/2 ) represents a similarity for single networks with 
disease (D), gene (G), and drug (Dr) layers respectively, and the block off-diagonal matrix 
represents the connections between different layers. 
 
2.2 Scoring algorithms for repurposing 
With the DGDr-Net, a scoring algorithm is applied to find repurposable drugs. Predicted resulting 
scores can be obtained simultaneously from each node of the disease layer, gene layer, and drug 
layer. In the disease layer, it is possible to obtain quantitatively how many associations between 
target and other diseases are. Disease scores for COVID-19 reflect both shared gene information 
with other diseases and comorbidity information. In the gene layer, disease-disease associations 
of the disease layer and protein interaction of the gene layer are propagated through the edges, 
and the resulting score indicates the priority of candidate target genes for treating COVID-19. In 
the drug layer, label information from COVID-19 in the disease layer is propagated through the 
edges of DGDr-Net. Resulting drug scores can identify the priority of candidate drugs for drug 
repurposing. Graph-based semi-supervised learning (SSL) is employed for scoring algorithms, as 
only one disease node (COVID-19) is given. SSL can perform predictions by propagating the label 
information to the nodes along with the edges even if there is only one labeled node18.  
The formulation of the scoring algorithm using SSL is as follows. Consider a DGDr-Net, 𝑮 =(𝑽, 𝑬, 𝑺), 	with node 𝑽(= 𝑽𝐃 ∪ 𝑽𝐆 ∪ 𝑽𝐃𝐫) corresponding to the 𝒏(= 𝒏𝐃 + 𝒏𝐆 + 𝒏𝐃𝐫) vertices. Let 𝒚 = (𝑦7, 	 … , 	𝑦8)𝐓  denote the label set of nodes, 𝒇 = P𝒇𝑫, 	𝒇𝑮, 	𝒇𝑫𝒓Q3 =R𝑓7/, … , 𝑓8$/ , 𝑓71, … , 𝑓8%1 , 𝑓7/2, … , 𝑓=$&/2 T3  denote the set of resulting scores, and 𝑾  be a similarity 
matrix of DGDr-Net.  Unlike the general classification problem where the target variable has a 
binary label (‘+1’ or ‘-1’), the problem setting of scoring in a semi-supervised approach has a unary 
label (‘+1’). More specifically, a disease node of COVID-19 19 (𝑣>?@A/! ) is set to a unary label 𝑦>?@A/ ∈ {+𝟏}, and the other nodes set to zero (𝒚\𝑦>?@A/ ∈ {𝟎}). There are two assumptions: a 
loss function (predicted scores in unlabeled nodes should be close to the given label of 𝑦$  in 
labeled nodes) and smoothness condition (predicted scores in adjacent unlabeled nodes should 
not be too different). These assumptions are reflected in the value of 𝒇 by minimizing the following 
quadratic function with the graph Laplacian matrix 𝑳: 𝐦𝐢𝐧 		(𝒇 − 𝒚)𝐓(𝒇 − 𝒚) + 𝝁𝒇𝐓𝑳𝒇                                                 (3) 
The graph Laplacian	𝑳 is defined as 𝑳 = 𝑫 −𝑾, where 𝑫 = 𝐝𝐢𝐚𝐠(𝒅𝒊), and 𝒅𝒊 = ∑ 𝒘𝒊𝒋𝒋 .	 The user-
specified parameter 𝜇 trades off loss and smoothness (to reduce complexity, 𝝁 is set to 𝟏/‖𝑳‖𝟏). 
Then, the solution of this problem becomes 	𝒇 = h𝑰 + 𝑳‖𝑳‖'jG𝟏 𝒚 .  The resulting score 𝑓  is 
rearranged in each layer: 𝒇H = 𝒇GJ'=	(𝒇)JNO(𝒇)GJ'=	(𝒇)  
To recommend the repurposable drugs, 𝒏𝐃𝐫 drugs are sorted in descending order according to 
the resulting score in drug layers. The rankings in drug lists can be analyzed in two ways: (1) to 
suggest possible candidate repurposable drugs and/or (2) to reduce the trial-and-error nature of 
current and future COVID-19 clinical trials.  
3. Results of Network Construction 
3.1 Data sources  
We collected a list of components and relational data from public databases. Table 1 describes 
the data sources used to construct DGDr-Net. For a single disease network, 5,819 diseases and 
31,991 disease-gene associations were obtained from the comparative toxicogenomics database 
(CTD)19. To screen diseases strongly associated with COVID-19 and to construct a more accurate 
COVID-19 centric disease network, community detection was applied20. 592 diseases were 
selected for disease nodes. To construct a gene network, we use the protein-protein interactions 
(PPIs) from the Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) databases. 
The STRING DB collects and integrates every possible publicly available PPIs from gene 
neighborhood, gene fusion, gene co-occurrence, gene co-expression, experiments/biochemistry, 
and annotated pathway data21. To avoid false positive information, we select 26,681 genes 
(proteins) and 841,068 interactions with the high confidence level (≥ 0.7).  For a drug network, 
9,540 drugs (compounds) and 525,207 drug-target gene associations were obtained from 
DrugBank and CTD databases19, 22.  
COVID-19 is associated with 17 genes for biomarker or therapeutic evidence (e.g., CCL2, TNF, 
IL10, CXCL8, IL6, IL1B, AGT, IL2, CXCL10, CCL3, TMPRSS2, IL7, IL2RA, CSF3, TMPRSS4, 
ACE2, and BSG) as shown in Figure 2a. Also, 194 drugs in our network are currently in clinical 
trials for COVID-1923. A more detailed description of data and how to construct networks is 
explained below.  
 
Table 1. List of data sources to construct DGDr-Net. 
 
Description # of data Data sources Released date 
Components 
Diseases 592 out of 5,819 
CTD, MeSH 
descriptor 2020-03-29 
Genes (Proteins) 26,681 STRING 2018-12-20 
Drugs (Compounds) 2,173 DrugBank, CTD 2020-04-22 
Relational 
data 
Disease-Gene 
associations 31,991 CTD  
Disease-Drug 
associations 76,889 DrugBank, CTD  
Protein-Protein 
Interactions 841,068 STRING  
Drug-Gene 
associations 9,540 DrugBank, CTD  
 Comorbidity diseases 18 
2-7  
 
3.2 Disease network construction 
The disease network is a sub-graph 𝐺 = (𝑉/,𝑊/) when 𝑆 = {𝑆/} in the multi-layered DGDr-Net. 
A set of nodes 𝑉/ represent a disease and 𝑊/ represents the similarity between diseases. To 
obtain the COVID-19 centric disease network, we construct and integrate two types of networks; 
(a) networks with disease-gene associations and (b) networks with comorbidity relations. In the 
framework for drug repurposing using disease interactome, the former network allows us to use 
genetic information for other related diseases while the latter network allows us to utilize clinical 
data. First, we constructed networks with disease-gene associations using 5,819 diseases and 
31,991 disease-gene associations. Each disease is represented as 26,681-dimensional gene 
vectors with binary attributes. If a disease is associated with a gene, its respective element in the 
disease vectors has a value (‘1’), otherwise (‘0’). (Note that attribute value 0 in disease vector 
does not mean that disease has no relationship with a certain gene. It could occur that the 
association has not been found yet). With 5,819 disease vectors, the edge weights for networks 
with disease-gene associations, 𝑊/7 , were calculated by Eq(1) using the cosine distance distR𝑣$ , 𝑣%T = 1 − R𝒗$ · 𝒗%T R‖	𝒗$‖ · p	𝒗%pTq . Next, we constructed a network with comorbidity 
relations involving the 18 aforementioned diseases highly comorbid with COVID-19. The 18 
aforementioned comorbid diseases were curated by recent researches2-7. The edge weights for 
comorbidity network, W/P , has binary values, each of which stands for reported comorbidity 
relation (‘1’) or not (‘0’). Figure 2(b) depicts a comorbidity network with 18 comorbidity diseases 
and COVID-19. To screen tightly associated diseases with COVID-19 and construct more eligible 
disease networks, community detection was applied20. Two modules include COVID-19 and 18 
comorbidity diseases. Finally, 592 diseases in two modules were used in the disease network. 
With two types of networks, network integration was performed. The combined similarity W/ is 
represented as a linear combination of both networks with coefficient 𝛽7  and 𝛽P . To find the 
coefficients 𝜷 for the linear combinations, grid search was performed in the range (0.1, 1) based 
on 𝛽7. While adjusting the coefficients, DGDr-Net was applied a scoring algorithm to aim for 
recommending clinical trial drugs for COVID-19, and average precision was used as a metric. As 
a result, we choose 𝛽7 = 0.3  for networks with disease-gene associations and 𝛽P = 0.7  for 
networks with comorbidity relation. Final disease networks are shown in Figure 2(c). 
3.3 Gene network construction 
Gene network is a sub-graph, 𝐺 = (𝑉1,𝑊1), when 𝑆 = {𝑆1} in DGDr-Net. The protein-protein 
interaction (PPIs) is employed for gene networks from the STRING database21. To avoid false 
positive information, we select 26,681 genes (proteins) and 841,068 interactions with a high 
confidence level (≥ 0.7). In the gene network, the edge stands for protein interaction, in which the 
edge weight indicates the presence or absence (‘1’ or ‘0’ respectively). 
3.4 Drug network construction 
Drug network is a sub-graph, 𝐺 = (𝑉/2,𝑊/2), when 𝑆 = {𝑆/2} in multi-layered DGDr-Net. 9,540 
drugs (compounds) and 525,207 drug-target gene associations were obtained from DrugBank 
and CTD databases19, 22. Each drug is composed of 26,681-dimensional binary attributes, each 
of which stands for existing target gene associations (‘1’) or not (‘0’). The similarity matrices for 
the drug network 𝑊/2 were calculated by cosine distance and transformed by Gaussian similarity 
kernel by Eq(1). 
3.5 Connections between different single layers 
Recall similarity matrix 𝑊 for DGDr-Net in Equation (2). The block off-diagonal matrix represents 
the connections between different layers. From the relational data in Table 1, the connection 
weights between different single layers have binary values of 1 if there are associations of two 
nodes in different layers, 0 otherwise.  
4. Scoring results for repurposable drugs and clinical implication 
4.1 Experimental Settings 
We performed a scoring algorithm to predict candidate repurposable drugs for COVID-19 using 
tripartite relationships of disease, gene, and drug in DGDr-Net. It can align drugs through the 
connections between nodes in the network with label propagations. Currently, no therapeutic 
drugs for coronavirus have been developed, which means that there are no ground truths that 
can be used as labeled data in machine learning perspective. SSL can deal with few labeled data 
and perform prediction by propagating the label information to the nodes in three layers along 
with edges18. To find repurposable drugs, we performed the scoring algorithms with a label for 
COVID-19 only in the disease layer. Also, all of the drug information related to COVID-19 were 
assumed to be unknown which means the edge connections between COVID-19 and all of the 
drugs were not included in the DGDr-Net. Out of 2,173 highlighted drugs, 194 drugs are currently 
in clinical trials for COVID-1923. To verify the performance of our scoring results, we assume these 
194 drugs as ground truths. Only one node (COVID-19) in the disease layer was set as “1” for the 
labeled set, and the remaining 590 diseases, 26,681 genes and 2,173 drugs were set as “0” for 
the unlabeled set. After scoring, we tested how many drugs in clinical trials were highly ranked. 
 
Figure 2. Snapshot of the disease network focused on COVID-19 and 18 comorbidity 
diseases: a) Disease-gene network, b) Reported comorbidity relationships with COVID-19, c) 
combined disease network 
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4.2 Implication and Validation of DGDr-Net 
The scoring algorithm with DGDr-Net provides score values for all nodes (disease, gene, drugs) 
in the three layers. Disease scores represent which diseases are strongly associated with COVID-
19, and gene scores represent the priorities of target genes for biomarkers. Also, drug scores 
represent the priorities of candidate drugs for COVID-19. Figure 3 shows the list of top 30 ranked 
diseases, genes, and drugs when COVID-19 is given. The colored nodes represent COVID-19 
related diseases, genes, and drugs, and they are sorted in descending order according to the 
resulting scores in each layer. Blue nodes indicate diseases, green nodes indicate the genes, and 
red nodes indicate the drugs that are recommended for repositioning. Also, we show the tripartite 
connections among diseases, genes, and drugs such as the disease-gene associations and drug-
disease associations.  
Figure 3(a) represents the associations between 30 high ranked diseases (blue nodes) and genes 
(green nodes) focused on COVID-19 (black node). The blue-colored circles indicate diseases with 
comorbidity information, and the blue outlined circles indicate diseases connected to COVID-19 
from sharing gene information. 18 diseases with comorbidity information are at the top of the 
ranking. Among them, 10 diseases (asthma, chronic obstructive pulmonary disease (COPD), HIV 
infections, cardiovascular diseases, cerebrovascular disorders, hypertension, hepatic cirrhosis, 
obesity, Alzheimer’s disease, and coronary artery disease) have strong associations with COVID-
19 because they not only have common genes with COVID-19 but also have additional 
comorbidity information factored in to the analysis. 8 diseases (kidney diseases, morbid obesity, 
common variable immunodeficiency, obstructive sleep apnea, chronic hepatitis B, chronic 
hepatitis C, chronic hepatitis, and diabetes mellitus) were connected with COVID-19 primarily via 
the comorbidity information. Among the comorbid diseases reported as an underlying medical 
condition, there was generally a positive correlation between the number of genes shared with 
COVID-19 and the given score. The remaining 12 diseases are linked by sharing gene hypothesis, 
and diseases with high edge weights have a high score. The score results in the gene layer is 
largely interpreted in two ways: (1) the priorities of the strongly associated genes with COVID-19 
and (2) a list of genes that can be candidate target genes for treatments. The priority of already 
known genes with COVID-19 is the result of the label propagation by reflecting both the disease 
interactions and protein interactions.  
Figure 3(b) represents the associations between diseases and candidate drugs. The red-colored 
circles in the drug lists denotes currently in clinical trial drugs and red outlined circles are currently 
not yet. As mentioned above, we have not yet developed a COVID-19 therapeutic agent. Thus, 
we recommend all 30 highlighted drugs as candidate repositioning drugs. The rankings in drug 
lists can be analyzed in two ways: (1) The results can suggest the possible candidate 
repurposable drugs from the rank, (2) To reduce the trial-and-error of clinical trials, the list of drugs 
can be compared with current clinical trial drugs for COVID-19.  
 
Figure 3. Associations between top 30 ranked diseases, genes, and drugs  
4.3 Clinical utility of the proposed drugs 
Figure 4 depicts the scoring results of top candidate drugs for COVID-19. On the graph, the solid 
gray line stands for the value of scores 𝑓 of the candidate drugs in descending orders. Out of 
2,173 drugs, we assume that these drugs should be repurposable drugs for COVID-19. The red 
circles on the line correspond to the current clinical trial drugs, and the black one is not. Steroids 
such as dexamethasone, prednisolone, and hydrocortisone were recommended as top 
candidates. Among them, dexamethasone, an anti-inflammatory drug, had the highest scores. 
Dexamethasone is a very cheap steroid that reduces inflammation by mimicking anti-inflammatory 
hormones produced by the body. COVID-19 treatment guidelines recommend using 
dexamethasone 6 mg per day for up to 10 days for hospitalized patients with COVID-1924, 25. On 
the score curve, the inserted drugs between clinical-trial drugs are regarded as strong candidates 
even though they are not used in clinical trials. 
Several proposed drugs need to be considered for clinical application. First, dexamethasone, 
prednisolone, and hydrocortisone are steroid analogues, which affect immune and inflammatory 
functions. There have been reports suggesting that steroids may be effective in the control of 
systemic inflammation or ‘cytokine storm’ in severe COVID-19 cases25, although there are several 
on-going trials on the effectiveness of steroid treatment10. The current study also supports the 
possibility of steroid therapy in patients with COVID-19. Until now, there has been controversy 
regarding the use of NSAIDs in COVID-19 patients. Although several literatures warned the use 
of NSAIDs, others disagreed26. With acetaminophen being included as one of the highlighted 
drugs in our study, we wish to bring attention to the role NSAIDs may play in helping an individual 
with COVID-19. Given the body’s inflammatory response to the virus, researchers have been 
studying the effects of some immune-modulating drugs including methotrexate, cyclosporin27, 28, 
although there is a paucity of information on other immune-modulating medications or cytotoxic 
drugs including azathioprine, doxorubicin, valproic acid, and Arsenic Trioxide. 
Based on the current study, further studies are needed to evaluate the possibility of immune-
modulating drugs in the context of COVID-19. Several proposed drugs also need attention such 
as ACE inhibitors (enalapril), lipid lowering medications (simvastatin), hormonal medication 
(estradiol, progesterone) and antidiabetic drugs (rosiglitazone, troglitazone). These medications 
may be more effective in specific populations with specific comorbidities such as kidney disease, 
diabetes, or coronary/cardiovascular disease. We may also have to evaluate the efficacy of these 
medications in specific populations. However, of course, before any of these potential treatments 
are given to help patients suffering from COVID-19, rigorous clinical trials are required.  
 
Figure 4. Score curve of top 30 repurposable drugs for COVID-19 
Pharmaceutical categories Drugs Rank Clinical Trials
Steroids
Dexamethasone 1 O
Prednisolone 7
Hydrocortisone 22 O
Hormonal medication Progesterone (steroid hormone) 14 O
Analgesics
Acetaminophen 13 O
Indomethacin (NSAIDs) 4
Ibuprofen (NSAIDs) 18 O
Diclofenac 23
Prostaglandin Dinoprostone (PGE2) 17
Cytotoxic medication
(chemotherapy)
Methotrexate 3 O
Doxorubicin 9
Valproic Acid 27
Arsenic Trioxide 28
Immunosuppressant
Cyclosporine 10 O
Azathioprine 29
ACE inhibitor Enalapril 16 O
Respiratory symptomatic treatment
Acetylcysteine (mucolytic agent) 25 O
Theophylline (bronchial dilator) 26
Lipid lowering medication Simvastatin 8 O
Antidiabetic drug
Rosiglitazone 15
Troglitazone 21
Element or Vitamin or
chemical compound
Zinc 6 O
Ascorbic Acid (Vit C) 11 O
Tretinoin (Vit A) 19 O
Nitric Oxide 24 O
Miscellaneous
Resveratrol 2
Quercetin 5
Estradiol 12
Curcumin 20
Atorvastatin 30 O
Dexamethasone
Resveratrol
Methotrexate
Indomethacin
Quercetin
Zinc
Prednisolone
Simvastatin
Doxorubicin
Cyclosporine
Ascorbic Acid
Estradiol
Acetaminophen
Progesterone
Rosiglitazone
Enalapril
Dinoprostone
Ibuprofen
Tretinoin
Curcumin
Troglitazone
Hydrocortisone
Nitric Oxide
Diclofenac
Acetylcysteine
Atorvastatin
Theophylline
Valproic Acid
Arsenic Trioxide
Azathioprine
5. Conclusions 
In this study, we developed a network-based drug repurposing framework for recommending 
repurposable drugs by utilizing and combining COVID-19 related data such as disease 
comorbidity, protein associations, and drug-target gene information. We first constructed a form 
of layered disease-gene-drug networks (DGDr-Net) to figure out the interactions among the 
diseases, genes, and drugs related to COVID-19. With the network, we apply semi-supervised 
scoring algorithms to identify candidate repurposable drugs. However, the information we have 
about coronavirus associated drugs is not yet sufficient because we do not yet have a cure for 
COVID-19. Therefore, in the scoring procedures, similar to the Cold Start Problem in 
recommendation systems, the candidate drugs were identified without any inferences between 
COVID-19 and drugs.  
We provided the priorities of candidate repurposable drugs and candidate target genes based on 
predicted scores. Of the top 30 drugs, 17 drugs were currently in clinical trials for the treatment of 
COVID-19. Steroids such as dexamethasone, prednisolone, and hydrocortisone are 
recommended as top candidates. Among them, dexamethasone, an anti-inflammatory drug, had 
the highest scores.  
A unique strength of our experimental approach is the inclusion of comorbidity factors to our 
network. This allowed us to more accurately identify repurposable drugs while affording a bird’s-
eye view of the intricate associations between COVID-19 and other related diseases, drugs, and 
genes. One particular limitation of our study is the relatively small sample size of the few 
databases we utilized; however, this concern is quickly alleviated as the robust yet flexible nature 
of a network-based approach allows us to very easily supplement and correct our current model. 
As we receive the newest information regarding the novel coronavirus, we can easily update the 
candidate drug/gene components of our networks, performing a set of updated calculations and 
generating an updated gene and drug candidate list almost instantly. With this in mind, we hope 
our approach may help clinicians and scientists make the hard decisions regarding which drugs 
or gene targets to test first in this global race for a cure. 
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